Abalonex, LLC
🇺🇸United States
Safety and Efficacy of ABX-101 in Participants Aged 18 to 50 Years of Age With Moderate to Severe Traumatic Brain Injury
Phase 2
Not yet recruiting
- Conditions
- Traumatic Brain InjuryCerebral Edema
- Interventions
- Drug: ABX-101 1mgDrug: ABX-101 2mg
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Abalonex, LLC
- Target Recruit Count
- 45
- Registration Number
- NCT06096415
© Copyright 2025. All Rights Reserved by MedPath